Expert Interview
Discussing the recent FDA approval of TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options for adult patients with moderately to severely active Crohn's disease
Ticker(s): JNJ, ABBV, LLYInstitution: GI Alliance
- Gastroenterologist at GI Alliance and active with the Crohn’s & Colitis Foundation, serving as co-chair of the National Scientific Advisory Committee (NSAC) Patient Education committee.
- Manages 150 patients with Crohn's disease.
- Clinical interests include inflammatory bowel diseases and he has served as Site Principal Investigator for multiple phase I-IV clinical trials in Crohn’s disease and ulcerative colitis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
